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ABSTRACT
Introduction: Adults with end-stage kidney disease
(ESKD) treated with haemodialysis experience mortality
of between 15% and 20% each year. Effective
interventions that improve health outcomes for long-
term dialysis patients remain unproven. Novel and
testable determinants of health in dialysis are needed.
Nutrition and dietary patterns are potential factors
influencing health in other health settings that warrant
exploration in multinational studies in men and women
treated with dialysis. We report the protocol of the
“DIETary intake, death and hospitalisation in adults
with end-stage kidney disease treated with
HaemoDialysis (DIET-HD) study,” a multinational
prospective cohort study. DIET-HD will describe
associations of nutrition and dietary patterns with
major health outcomes for adults treated with dialysis
in several countries.
Methods and analysis: DIET-HD will recruit
approximately 10 000 adults who have ESKD treated by
clinics administered by a single dialysis provider in
Argentina, France, Germany, Hungary, Italy, Poland,
Portugal, Romania, Spain, Sweden and Turkey.
Recruitment will take place between March 2014 and
June 2015. The study has currently recruited 8000
participants who have completed baseline data.
Nutritional intake and dietary patterns will be measured
using the Global Allergy and Asthma European
Network (GA2LEN) food frequency questionnaire.
The primary dietary exposures will be n-3 and n-6
polyunsaturated fatty acid consumption. The primary
outcome will be cardiovascular mortality and
secondary outcomes will be all-cause mortality,
infection-related mortality and hospitalisation.
Ethics and dissemination: The study is approved
by the relevant Ethics Committees in participating
countries. All participants will provide written informed
consent and be free to withdraw their data at any time.
The findings of the study will be disseminated through
peer-reviewed journals, conference presentations and
to participants via regular newsletters. We expect that
the DIET-HD study will inform large pragmatic trials of
nutrition or dietary interventions in the setting of
advanced kidney disease.
BACKGROUND
Long-term dialysis treatment for end-stage
kidney disease is associated with an annual
Strengths and limitations of this study
▪ The study includes a large population and com-
prehensive validated food frequency question-
naire across a diverse range of countries to
investigate nutritional patterns and associated
outcomes in adults treated with haemodialysis.
▪ The accumulated data from this study will inform
large pragmatic interventional studies.
▪ Outcome data will be measured using registry
linkages, which increases the feasibility of the
large sample size but may lead to some limita-
tions in outcome adjudication.
▪ The observational study design is hypothesis
generating due to potential confounding from
measured and unmeasured variables.
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mortality of between 15% and 20%, a proportion in
excess of many cancers.1 Healthcare interventions have
not been generally shown to improve clinical outcomes
for adults treated with dialysis and additional testable
strategies for improving mortality and morbidity are
needed.
Nutritional intake and dietary patterns are potential
determinants of health outcomes in dialysis patients.
Dietary restrictions aimed at keeping ﬂuid, serum
phosphorus and potassium levels within range often result
in limited food choices and unappetising meals.2 The
accumulation of uraemic metabolites, metabolic acidosis,
inﬂammation and additional frequent comorbidities,
including cardiac dysfunction, can suppress appetite,
decrease protein and energy intake and increase catabolic
processes in this population.3 Malnutrition (commonly
referred to as protein-energy wasting4) affects 20–70% of
dialysis patients and increases with duration of dialysis
treatment.5–7 Approximately 5–10% of people treated with
dialysis experience severe protein-energy malnutrition.8
Premature death in people with end-stage kidney
disease is strongly associated with low body mass, low
serum cholesterol and other markers of impaired nutri-
tion. Several studies have shown a consistent association
between low serum albumin, low height-adjusted body
weight and malnutrition (assessed by subjective global
assessment) and total and cardiovascular-speciﬁc mortal-
ity in the dialysis population.9–11 In addition, protein-
energy wasting (incorporating malnutrition and other
metabolic derangements in patients with end-stage
kidney disease, such as inﬂammation) is a strong risk
factor for premature death.3 Data for 5058 adults in the
US Renal Data System (USRDS) indicated that dialysis
patients who were considered malnourished by their phy-
sicians had a 27% greater risk of cardiovascular death.
Similarly, a Dialysis Outcomes and Practice Patterns Study
(DOPPS) cohort study comprising 7719 adult haemodi-
alysis patients reported that severe malnutrition (evalu-
ated by a modiﬁed subjective global assessment, recent
weight loss, poor dietary intake, gastrointestinal symp-
toms and visual assessment of subcutaneous fat) was
linked to a 33% higher mortality risk.11 12
Serum n-3 and n-6 polyunsaturated fatty acid proﬁles
are additional potential determinants of cardiovascular
outcomes in adults treated with haemodialysis. N-3 poly-
unsaturated fatty acids such as eicosapentaenoic acid
and docosahexaenoic acid may favourably inﬂuence oxi-
dative stress, inﬂammation and thrombosis.13 14 Dialysis
patients have a decreased ratio of n-3 to n-6 PUFAs,
which independently predicts accelerated cardiovascular
disease.15 However, data for dietary polyunsaturated fatty
acid intake and associations with mortality in this clinical
setting are sparse, although n-3 polyunsaturated fatty
acid supplementation may lower mortality and hospital
admissions in other settings of chronic disease,16 includ-
ing earlier stages of chronic kidney disease.17
Other dietary and nutrition factors have potential
clinical effects in the setting of end-stage kidney
disease. The Mediterranean diet, characterised by high
intake of olive oil, fruit, nuts, vegetables and cereals,
moderate ﬁsh and poultry intake and lower consump-
tion of dairy foods, red and processed meats and
sweets, prevents cardiovascular events,18 although prog-
nostic data in the setting of kidney disease are rare.
The average blood levels of biologically important trace
elements including selenium and zinc (antioxidant
molecules) differ in people with end-stage kidney
disease.19 Lower zinc levels in patients with end-stage
kidney disease are associated with increased oxidative
stress, lipid peroxidation and inﬂammation.20 Since
deﬁciency or excess of trace elements is potentially
harmful, the hypothesis that trace element supplemen-
tation might inﬂuence clinical outcomes is worthy of
evaluation. Similarly, vitamin C is an antioxidant with
several immune and regulatory functions, and levels
are often depleted in patients with end-stage kidney
disease by up to 50%. A recent Cochrane review of
trials investigating the use of antioxidants for people
with chronic kidney disease found that antioxidant
therapy does not reduce cardiovascular or all-cause
death but, due to the suboptimal quality of existing
studies, a clinically important beneﬁt cannot be
excluded.21
The quality and quantity of food intake may play a
role in cardiovascular and infection related complica-
tions in the dialysis setting. In addition, dietary patterns
may have prognostic implications for patients through
mechanisms independent of nutritional status.22 23
However, data evaluating the association between diet
and clinical outcomes in people treated with dialysis are
limited and largely derive from small, single-centre,
retrospective studies.24–27
The prospective study described in this protocol will
be the ﬁrst large-scale multinational cohort study to
evaluate the association between nutrition and health
outcomes in adults with end-stage kidney disease treated
with haemodialysis. The study will assess the short-term
and long-term morbidity and mortality associated with
dietary intake (total energy, fat (including monounsatu-
rated and n-3 and n-6 polyunsaturated fatty acids; choles-
terol), carbohydrates (including total sugars), protein,
ﬁbre, folate, β-carotene, retinol, thiamine, riboﬂavin,
phosphorus, magnesium, calcium, zinc, ﬂuid, and spe-
ciﬁc food types (fruit, vegetable, nuts, ﬁsh, pulses)) in
adults treated with haemodialysis. The study will also
evaluate nutrient and non-nutrient antioxidants, speciﬁc
food groups related to Mediterranean or other region-
ally distinctive diets and the intake of processed food
and fresh fruit and vegetables.
METHODS AND ANALYSIS
Study design summary
The “DIETary intake, death and hospitalisation in adults
with end-stage kidney disease treated with HaemoDialysis
(DIET-HD) study” is a multinational prospective cohort
2 Palmer SC, et al. BMJ Open 2015;5:e006897. doi:10.1136/bmjopen-2014-006897
Open Access
group.bmj.com on March 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
study designed to evaluate the association between nutri-
tion and dietary patterns and health outcomes in preva-
lent adult haemodialysis patients in Europe and South
America. The study is currently recruiting.
Target population, setting and inclusion/exclusion criteria
The DIET-HD population will recruit approximately
10 000 adults treated with long-term haemodialysis treat-
ment at clinics within a multinational collaborative dialy-
sis network administered by Diaverum, a provider of
renal services. Recruitment will take place between
March 2014 and June 2015. Overall, 8000 participants
have been recruited by February 2015. The clinics
included in this study will be from dialysis communities
in which the local investigators have committed to pro-
viding high-quality data in Argentina, France, Germany,
Hungary, Italy, Poland, Portugal, Romania, Spain,
Sweden and Turkey.
Participants will be eligible for DIET-HD if they meet
the following inclusion criteria: (1) have end-stage
kidney disease; (2) are treated with long-term haemodi-
alysis for at least the previous 90 days; (3) are 18 years or
older; (4) their treating team agrees to the patient’s
involvement in the study and (5) the participant is
willing to provide written and informed consent. We will
exclude potential participants from DIET-HD if they
have: (1) signiﬁcant neurocognitive disability or medical
comorbidity that would preclude them from understand-
ing the dietary questionnaire even if assisted; (2) a life
expectancy less than 6 months according to their treat-
ing physician or (3) planned kidney transplantation
within 6 months of baseline.
Study exposures and outcomes
The primary exposure variables will be dietary consump-
tion of n-3 and n-6 polyunsaturated fatty acids. The
primary outcome will be cardiovascular mortality.
Secondary outcomes will be all-cause mortality, death due
to infection and all-cause and cause-speciﬁc hospitalisa-
tion. The key secondary nutritional exposure variables will
be dietary total energy, fat (including monounsaturated
fatty acids; cholesterol), carbohydrates (including total
sugars), protein, ﬁbre, folate, β-carotene, retinol, thiamine,
riboﬂavin, phosphorus, magnesium, calcium, zinc, ﬂuid,
and speciﬁc food types (fruit, vegetable, nuts, ﬁsh, pulses).
Study procedures
Assessment of dietary intake (food frequency questionnaire)
Consecutive eligible patients in a convenient sample of
selected clinics will be given a food frequency question-
naire (FFQ) to complete during dialysis treatment. The
usual dietary intake will be ascertained using the Global
Allergy and Asthma European Network (GA2LEN) FFQ.28
GA2LEN was initially translated into 12 languages to be
used as a single instrument in all the European centres
participating in the GA2LEN follow-up survey. The FFQ
has been tested in a subsample of adults from ﬁve
European countries and shown to be a reliable instrument
to estimate dietary intake in different countries.28
Translations of the FFQ have been carried out following
the standard operating procedure of the WHO. Forward
translation from English into relevant participant lan-
guages was carried out by local research team members.
Back translation was then carried out by an independent
translator who had not seen the original English version.
During this stage, local foods were incorporated into each
of the FFQs. GA2LEN has been adapted to mirror the
local and staple foods of each participant country in this
study without affecting the international comparability
structure of the FFQ. The FFQ provides information on
the frequency of a wide range of foods, which have been
classiﬁed using the European Food Group Classiﬁcation
Method designed by Ireland et al.29 This is an international
classiﬁcation based on the European Food Consumption
Survey Method (EFCOSUM) designed to “deﬁne a
minimum set of dietary components which are relevant
determinants of health and to deﬁne a method for the
monitoring of food consumption in national representa-
tive samples of all age-gender categories in Europe in a
comparable way.”30
Nutrient estimates
Nutrient intake will be calculated using national Food
Composition Tables from each participating country.
For analyses comprising the entire study sample, we
will implement the methodological approach used
by GA2LEN,28 which employed the British Food
Composition Table to describe nutrient composition,
including data from country-speciﬁc Food Composition
Tables, to calculate nutrient estimates of traditional or
staple foods of speciﬁc countries. Current analyses in
the GA2LEN Nutrition study show that the British Food
Composition Table is the most comprehensive table in
terms of number of nutrient data available. We have
access to all the latest data within Food Composition
Tables in European countries facilitated by EuroFir
(European Food Network of Excellence)31 which, as
GA2LEN, was a European Union funded Network. This
is now a non-proﬁt consortium that fosters the advance-
ment in the knowledge of food composition in Europe
and other countries.
The standard food portion sizes used in the FFQ will
be obtained from Food Standard Agency Food Portion
Sizes Guidelines in the UK. The frequency of consump-
tion will be converted into grams per day and then into
nutrient estimates. The FFQ is designed to be answered
by the participants (self-administered). However,
depending on the country and the needs of the research
team, as well as of the participants, some centres will
prefer to have the FFQ interviewer administered, when
necessary, or have interviewers on hand in the clinics to
either administer the FFQ (for participants who have lit-
eracy limitations) or to verify that the FFQ has been
answered in full. Participants will complete the dietary
questionnaire during a haemodialysis treatment.
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We will calculate intake of the following macronutri-
ents and micronutrients using estimates of the EuroFir
Food Composition Tables: energy (kJ/day), fat (includ-
ing monounsaturated and polyunsaturated fat; n-3 poly-
unsaturated fatty acids; n-6 polyunsaturated fatty acids;
trans-fatty acids; cholesterol), carbohydrate, glycaemic
index, total sugar, protein (including sources (animal vs
vegetable sources)), ﬁbre, folate, β-carotene, retinol,
thiamine, riboﬂavin, phosphorus, magnesium, calcium
and zinc. We will also estimate the intake of speciﬁc
food groups including fruit, vegetable, nuts, ﬁsh and
pulses. Research assistants will be trained using a
step-by-step practical overview of the process that is to be
followed in administration of the questionnaires. The
protocol emphasises the need for assistants to avoid non-
verbal cues indicating surprise or disapproval at the par-
ticipant’s eating patterns.
FFQ responses will be evaluated by members of the
research team who are unaware of the participants’
identities. All FFQs with missing values will be checked
and corrected for any data errors. After data cleaning, if
more than 10% of the questionnaire remains incom-
plete, then the participant will be excluded. In addition,
individuals for whom energy intake is in the upper or
lower 2% of the intake will then be checked for data
entry and coding accuracy and errors will be corrected,
if identiﬁed. Data from the FFQ will be entered into an
electronic database using optical character recognition
and analysed using software that facilitates the collection
of food recalls in a standardised fashion.32
Demographic and clinical data
Demographic, clinical, laboratory and dialysis-related
data will be obtained from a patient database within
1 month of enrolment. Relevant data will be obtained
from clinical databases linked to the participant via a
standardised identiﬁcation code. Standardised data will
include age, gender, race, country of residence, clinic
attended, education, marital and occupational status,
family income, ﬁnancial stress, housing, alcohol intake,
smoking history, physical activity, menopausal status,
body mass index, protein catabolic rate, cause of kidney
disease, existence of cardiovascular comorbidity, dia-
betes, or hypertension, medication prescription, dialysis
prescription, time on dialysis, and serum levels of
haemoglobin, phosphorus, parathyroid hormone,
calcium, ferritin, albumin and total cholesterol.
Outcomes
Measurement time points
After baseline dietary evaluation, we will measure clinical
outcomes using linked data at 12 months and thereafter
at yearly intervals up to 10 years. Data for total and
cause-speciﬁc hospitalisation and mortality are obtained
through data linkages to a centralised database adminis-
tered by Diaverum. In this database, every change in par-
ticipant status is updated by the managing clinician on a
monthly basis, including change in survival status or hos-
pitalisation, with causes of death or hospital admission.
Outcomes
The primary study outcome will be cardiovascular
mortality. Secondary outcomes will be all-cause mortality,
infection-related mortality and all-cause and cardiovascular-
related hospitalisation. A cardiovascular-related death or
hospitalisation will include death or hospitalisation
attributed to acute myocardial infarction, pericarditis,
atherosclerotic heart disease, cardiomyopathy, cardiac
arrhythmia, cardiac arrest, valvular heart disease, pul-
monary oedema, congestive cardiac failure, cerebrovas-
cular accident including intracranial haemorrhage,
ischaemic brain damage including anoxic encephalop-
athy, or mesenteric infarction or ischaemic bowel. An
infection-related death will include septicaemia due to
internal vascular access, central nervous system infection
(brain abscess, meningitis, encephalitis), septicaemia
due to peripheral vascular disease or gangrene, cardiac
infection (endocarditis), pulmonary infection (pneumo-
nia or inﬂuenza), abdominal infection (peritonitis,
perforated bowel, diverticular disease, gallbladder infec-
tion) or genitourinary infection (urinary tract infection,
pyelonephritis, renal abscess).
Sample size
The sample size for this study will be approximately
10 000 participants. On the basis of previous validation
data for the FFQ28 and our experience during recruit-
ment of 8000 participants, we anticipate that approxi-
mately 10% of participants will not provide a completed
survey and that 5% of the patient population will leave
the network for reasons other than mortality, transplant-
ation or withdrawal from dialysis, leaving a potential ana-
lysable population of 8500. On the basis of an
anticipated mortality of 14–15% each year and a cardio-
vascular mortality rate of 6% per annum, we anticipate
that recruitment and evaluation of at least 6000 partici-
pants will allow a study with a type 1 error α=0.05 and
power of 80% to detect an HR of at least 1.10 for each 1
SD decrease in n-3 polyunsaturated fatty acid intake.
When adjusting for the complete set of potentially con-
founding variables, assuming an R2=0.30, the same
sample size will detect an HR of at least 1.12 for each SD
decrease in the primary exposure.
Statistical analysis
The initial data analysis will be descriptive. Participants’
baseline characteristics (country, clinic, demographics,
clinical characteristics, dialysis treatment, etc) will be
described using frequencies for categorical variables and
mean, median, range and SD for continuous variables.
Characteristics of speciﬁc dietary components will also
be calculated as mean, median, range and SD. To evalu-
ate associations between each individual nutrient of
interest and the outcomes, we will conduct multivariate
regression analyses using Cox proportional hazards
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analysis ﬁtted using a shared frailty model to account for
clustering within countries. Participants will be censored
within survival analyses if they emigrate from the dialysis
network, are transplanted or experience recovery of
their kidney function.
Given the large number of nutritional exposures, we
will control for potential false discoveries using the
Simes’ procedure allowing for a 5% false discovery rate
while controlling for potential confounding variables.
Similarly, we will explore associations between groups of
foods (eg, vegetables or fruits) and nutrients using
similar techniques. We will then explore the association
between dietary or nutritional exposures (foods, single
or grouped or nutritional components) and the out-
comes of interest within countries using logistic or linear
regression adjusted by confounding variables and then
combine data from all countries using meta-analysis. We
will consider the gross national product and income
equality in analysis. We will also calculate weighting of
the sample to make it representative of the source popu-
lation within each country. We will conduct analyses in
STATA (http://www.stata.com) using existing routines
available for the GA2LEN study.
ETHICS AND DISSEMINATION
Ethical approval
The study is based on informed written consent, and
participants can withdraw from the study at any point in
time. The study is non-invasive and imposes no signiﬁ-
cant risks to participants. Data material will be managed
conﬁdentially and anonymously.
Dissemination
The ﬁndings of the study will be disseminated through
peer-reviewed journals, national and international con-
ference presentations and to the participants through
communication within the dialysis network in which this
study is conducted via a regular newsletter.
DISCUSSION
We have designed DIET-HD to evaluate whether
dietary patterns and nutritional intake are associated
with mortality and hospitalisation in adults with end-
stage kidney disease treated with haemodialysis. This
study will generate potential testable diet and nutrition
targets for evaluation in pragmatic multicentre trials
and meta-analyses.
Our study design, while incorporating data from
several countries and using validated and robust multi-
national dietary analysis tools from the GA2LEN network
collaboration, has potential limitations. To ensure sufﬁ-
cient data from a broad range of participants, we have
used a convenient sample of clinics within the participat-
ing countries to maximise recruitment without stratiﬁca-
tion by key clinic demographic or clinical characteristics.
This may limit our ability to provide data representative
of source populations but will still be the largest
in-depth nutritional survey of adults treated with haemo-
dialysis to date. In addition, as our patient population is
>95% European, we will lack generalisable data for
non-European ethnicities. Mortality and other end point
data will be obtained using linkages to a data registry.
There will not be adjudication of clinical end points by
personnel blinded to exposure and there will be some
misclassiﬁcation of clinical outcomes.
Effective strategies to improve health outcomes in this
population are scarce and urgently needed. We expect
that the results of the DIET-HD study will inform large
pragmatic trials of nutrition or dietary interventions in
the setting of advanced kidney disease.
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